Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.51 |
| ▸ | TAS2R8 | Q9NYW2 | 2/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16260552 | 0.84 | CYP19A1 (0.50) | CYP19A1CYP11B1CYP11B2TAS2R8KLKB1 | |
| SCHEMBL15759268 | 0.83 | KLKB1 (0.51) | KLKB1 | |
| SCHEMBL18232748 | 0.82 | CREBBP (0.60) | CYP19A1CYP11B1CYP11B2TAS2R8KLKB1 | |
| SCHEMBL19077891 | 0.81 | CYP19A1 (0.51) | CYP19A1CYP11B1CYP11B2KLKB1 | |
| SCHEMBL28419208 | 0.81 | CYP19A1 (0.54) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL15520797 | 0.81 | MAPT (0.62) | CYP19A1CYP11B1CYP11B2KLKB1 | |
| SCHEMBL13813853 | 0.80 | KCNH2 (0.53) | KLKB1 | |
| SCHEMBL16246747 | 0.80 | KLKB1 (0.49) | KLKB1 | |
| SCHEMBL17232474 | 0.80 | KLKB1 (0.49) | KLKB1 | |
| Hydrochloric Acid SCHEMBL21492793 | 0.78 | LOXL2 (0.53) | CYP19A1CYP11B1CYP11B2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3400221-B1 | PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2017120194-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | CYP19A1 2000/4885CYP11B1 1760/4885CYP11B2 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.